These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26108299)

  • 1. Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update.
    Niemeijer MN; van den Berg ME; Eijgelsheim M; Rijnbeek PR; Stricker BH
    Drug Saf; 2015 Oct; 38(10):855-67. PubMed ID: 26108299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug- and non-drug-associated QT interval prolongation.
    van Noord C; Eijgelsheim M; Stricker BH
    Br J Clin Pharmacol; 2010 Jul; 70(1):16-23. PubMed ID: 20642543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic issues in thorough QT trials.
    Judson RS; Salisbury BA; Reed CR; Ackerman MJ
    Mol Diagn Ther; 2006; 10(3):153-62. PubMed ID: 16771601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
    Shah RR
    Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on risk factors for drug-induced arrhythmias.
    Vlachos K; Georgopoulos S; Efremidis M; Sideris A; Letsas KP
    Expert Rev Clin Pharmacol; 2016; 9(1):117-27. PubMed ID: 26460585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug-induced QT interval prolongation: do we know the risks?].
    Villamañán E; Armada E; Ruano M
    Med Clin (Barc); 2015 Mar; 144(6):269-74. PubMed ID: 24656122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants.
    Lopez-Medina AI; Chahal CAA; Luzum JA
    Pharmacogenomics; 2022 Jun; 23(9):543-557. PubMed ID: 35698903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
    Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
    Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM; Anderson IM
    Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations.
    Buffery PJ; Strother RM
    N Z Med J; 2015 Jun; 128(1416):66-74. PubMed ID: 26117678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database].
    Rochoy M; Auffret M; Béné J; Gautier S;
    Rev Epidemiol Sante Publique; 2017 Feb; 65(1):1-8. PubMed ID: 27988172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced fatal arrhythmias: Acquired long QT and Brugada syndromes.
    Turker I; Ai T; Itoh H; Horie M
    Pharmacol Ther; 2017 Aug; 176():48-59. PubMed ID: 28527921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths.
    Martinez-Matilla M; Blanco-Verea A; Santori M; Ansede-Bermejo J; Ramos-Luis E; Gil R; Bermejo AM; Lotufo-Neto F; Hirata MH; Brisighelli F; Paramo M; Carracedo A; Brion M
    Forensic Sci Int Genet; 2019 Sep; 42():203-212. PubMed ID: 31376648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT interval and drug therapy.
    Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome.
    Kaufman ES
    Heart Rhythm; 2009 Aug; 6(8 Suppl):S51-5. PubMed ID: 19631908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of cardiac K(+) channels.
    Escande D
    Eur J Pharmacol; 2000 Dec; 410(2-3):281-287. PubMed ID: 11134676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes.
    Ramalho D; Freitas J
    Rev Port Cardiol (Engl Ed); 2018 May; 37(5):435-446. PubMed ID: 29636202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prolongation of QT interval and evaluation of safety of drugs].
    Li Y; Xu J; Zhang W
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Aug; 30(4):905-8. PubMed ID: 24059079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study.
    Newton-Cheh C; Guo CY; Larson MG; Musone SL; Surti A; Camargo AL; Drake JA; Benjamin EJ; Levy D; D'Agostino RB; Hirschhorn JN; O'donnell CJ
    Circulation; 2007 Sep; 116(10):1128-36. PubMed ID: 17709632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.